vaccine

Personalized melanoma vaccine reduced risk of recurrence and death by 42% in a major study

In a clinical trial involving more than 1,100 patients, the personalized mRNA vaccine Intismeran in combination with the immunotherapy Keytruda reduced the risk of death or melanoma recurrence by 42%, and the risk of spread by 38% over two years. MSD and Moderna are preparing to file for registration. Experts call the result important but demand long-term follow-up.